(2 years, 5 months ago)
Commons ChamberWe are providing the fastest ever sustained uplift in R&D funding, reaching £20 billion per annum by 2024-25. If association to Horizon Europe is not possible in good time to make the most of that programme, we will take forward a bold and ambitious package of UK alternatives.
This country has been world-leading in its covid-19 vaccination programme and so much more in our pharmaceutical industries as well as the health sector. Can the Minister say a little more about what specific research and development investment will go into pharmaceuticals and the health sector? I would particularly like to mention cancer services and Alector oncology in my constituency which is expanding.
My hon. Friend has always been a passionate advocate and defender of business in the Crawley constituency, specifically R&D projects and innovation, and I am glad he mentioned Alector and others, as they are important companies in his constituency. We continue to support investment in R&D through a vibrant research and innovation system that attracts private sector investment and drives up productivity across the UK, including in Crawley.
(3 years, 5 months ago)
Commons ChamberWe will be responding in due course to the call for input on going further on a trade deal with Canada, and we are looking forward to that negotiation starting in the autumn. I would remind the hon. Member that there are no ISDS provisions in the UK-Australia deal, but I would also remind her that the UK has never lost an ISDS case. We do have ISDS provisions in quite a number of our existing agreements, and the UK has never lost any such case.